Launches program in North Carolina, California and Texas with a focus on military veterans and service members transitioning to civilian careers
Wilmington, N.C. – Pharmaceutical Product Development, LLC (PPD) today announced its launch of a clinical research associates (CRAs) apprenticeship program targeted to military veterans and military service members with medical backgrounds who are transitioning to the civilian workforce. PPD’s initiative, the first CRA apprenticeship program registered with the U.S. Department of Labor, will begin in North Carolina, Texas and California in the first quarter of this year.
“As a veteran who transitioned to the civilian workforce, I understand the need to provide viable career opportunities to those who have served,” said William Sharbaugh, chief operating officer of PPD. “Our industry-first CRA apprenticeship program recognizes the skills of veterans and transitioning service members with medical backgrounds who, through their service, have developed the requisite skills of leadership and who are motivated to join us in helping deliver life-changing medicines.”
PPD’s 12-month program, which provides training through PPD’s award-winning CRA academy and on-the-job learning, is designed to give participants the foundation to be qualified and successful CRAs. The competency-based program provides exposure to three clinical roles, allowing apprentices to build on what they’ve learned and gradually integrate into the contract research industry.
“PPD recognizes the need for highly skilled professionals to ensure the quality of clinical trials,” said Ed Murray, executive vice president and chief human resources officer of PPD. “With this program, PPD addresses one of the immediate needs of military veterans and personnel transitioning to civilian careers, while addressing a clear need to expand the talent pool of CRAs for the conduct of clinical research.”
NCWorks, the North Carolina approving agency for the U.S. Department of Labor, and the Office of Apprenticeship in California and in Texas approved PPD’s application to make the role of clinical research associate (clinical documentation improvement specialist) a recognized occupation for registered apprenticeship programs.
PPD is responsible for the coordination, administrative processes and all programming aspects, including recruitment and marketing, of the apprenticeship. In establishing the program, PPD draws on decades of experience in recruiting and developing CRAs. In 2016 PPD won the Outstanding Training Initiative Award for its Virtual Clinical Foundations Program 2.0, which prepares CRAs for success in monitoring clinical trials.
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.